Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of LMP744 in Advanced Solid Tumors and Lymphomas
NCT03030417Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2017
- Primary completion
- Oct 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LMP744 in solid tumor and lymphoma, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose. Started Feb 2017; status: completed.
02
Drugs
LMP744
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03030417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030417.